These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 24724913)

  • 1. Evaluating national guidelines for the prophylactic treatment of respiratory syncytial virus in children with congenital heart disease.
    Granbom E; Fernlund E; Sunnegårdh J; Lundell B; Naumburg E
    Acta Paediatr; 2014 Aug; 103(8):840-5. PubMed ID: 24724913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of palivizumab in infants with congenital heart disease.
    Yount LE; Mahle WT
    Pediatrics; 2004 Dec; 114(6):1606-11. PubMed ID: 15574622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Appropriate prophylaxis with restrictive palivizumab regimen in preterm children in Sweden.
    Navér L; Eriksson M; Ewald U; Linde A; Lindroth M; Schollin J
    Acta Paediatr; 2004 Nov; 93(11):1470-3. PubMed ID: 15513574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
    Romero JR
    Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylaxis protects infants with congenital heart disease from severe forms of RSV infection: an Italian observational retrospective study : Palivizumab prophylaxis in children with congenital heart disease.
    Ratti C; Greca AD; Bertoncelli D; Rubini M; Tchana B
    Ital J Pediatr; 2023 Jan; 49(1):4. PubMed ID: 36631870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis with palivizumab against respiratory syncytial virus infection in infants with congenital heart disease--who should receive it?
    Sunnegårdh J
    Acta Paediatr; 2006 Apr; 95(4):388-90. PubMed ID: 16720482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):e620-38. PubMed ID: 25070304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of respiratory syncytial virus-related hospitalizations in high-risk children: follow-up of a national cohort of infants treated with Palivizumab as RSV prophylaxis.
    Lacaze-Masmonteil T; Rozé JC; Fauroux B;
    Pediatr Pulmonol; 2002 Sep; 34(3):181-8. PubMed ID: 12203846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
    Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
    Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nationwide survey of palivizumab for respiratory syncytial virus prevention in Japanese children with congenital heart disease.
    Saji T; Nakazawa M; Harada K
    Pediatr Infect Dis J; 2008 Dec; 27(12):1108-9. PubMed ID: 18978515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hospital admission of high risk infants for respiratory syncytial virus infection: implications for palivizumab prophylaxis.
    Heikkinen T; Valkonen H; Lehtonen L; Vainionpää R; Ruuskanen O
    Arch Dis Child Fetal Neonatal Ed; 2005 Jan; 90(1):F64-8. PubMed ID: 15613580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prophylaxis in RSV infection (Palivizumab)--is it worthwhile?
    Hashmi NA; Cosgrove JF; MacMahon P
    Ir Med J; 2000 Dec; 93(9):284. PubMed ID: 11209917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Respiratory syncytial virus prophylaxis in preterm infants: a cost-effectiveness study from Turkey.
    Oncel MY; Mutlu B; Kavurt S; Baş AY; Demirel N; Akyol M; Erdeve O; Dilmen U
    Turk J Pediatr; 2012; 54(4):344-51. PubMed ID: 23692714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
    ;
    Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologic risk factors for respiratory viral infections and immunoprophylaxis for respiratory syncytial virus in young children with congenital heart disease.
    Cabalka AK
    Pediatr Infect Dis J; 2004 Jan; 23(1 Suppl):S41-5. PubMed ID: 14730269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RSV prophylaxis guideline changes and outcomes in children with congenital heart disease.
    Walpert AS; Thomas ID; Lowe MC; Seckeler MD
    Congenit Heart Dis; 2018 May; 13(3):428-431. PubMed ID: 29436781
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hospitalization for respiratory syncytial virus illness in Down syndrome following prophylaxis with palivizumab.
    Paes B; Mitchell I; Yi H; Li A; Lanctôt KL;
    Pediatr Infect Dis J; 2014 Feb; 33(2):e29-33. PubMed ID: 23989104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing the delivery and use of a new monoclonal antibody in children with congenital heart disease: a successful provincial respiratory syncytial virus prophylaxis program.
    Warren A; Langley JM; Thomas W; Scott J
    Can J Cardiol; 2007 May; 23(6):463-6. PubMed ID: 17487291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Respiratory virus prophylaxis in congenital heart disease.
    Joshi M; Tulloh RM
    Future Cardiol; 2018 Sep; 14(5):417-425. PubMed ID: 29877720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.